If ASCO 2021 proves anything, it’s that the explosion in immuno-oncology therapies over the last few years shows no signs of slowing down. As the field becomes more crowded, digital tools may be critical for improving outcomes, says a new whitepaper. The whitepaper, ‘The Role of Digital Health in Immuno-oncology Therapy Development and Adoption’ from …
Digital health thought leader Mark Tarby, BrightInsight vice president of regulatory and quality management systems, shared his take on what the EU MDR means for connected devices, Software as a Medical Device (SaMD), and the go-to market strategies for the companies behind them.
Today on Health in 2 Point 00, I’m getting my shots soon! On Episode 197, General Catalyst is throwing more money around – $101 million goes to BrightInsight for its digital health insights management platform. SteadyMD raises $25 million bringing its total to $31 million, and CirrusMD raises $20 million in a Series C bringing …
BrightInsight, a startup developing infrastructure to make it easier for companies to make their own health apps, raised $101 million in funding. General Catalyst led the series C round.
AstraZeneca is turning to digital technology to help patients and clinicians manage the treatment of chronic diseases. Though this technology isn’t tied to any AstraZeneca drug, the company believes such digital tools will become part of the new standard of care.
In an interview, BrightInsight Co-founder and CEO Kal Patel, MD, offered a preview of the report, The Role of Digital Health in Immuno-oncology Therapy Development and Adoption.
The disruption to biopharma and medtech businesses caused by Covid-19, such as product launch and clinical trial delays, has underscored the need for a more digital focused strategy.